Tianjin Tianyao Pharmaceuticals' subsidiary Compound Potassium Dihydrogen Phosphate Injection passed the consistency evaluation of generic drugs.

Tianjin Tianyao Pharmaceuticals (600488.SH) announced that its subsidiary, Tianjin Heyao Heping Pharmaceutical Co., Ltd. (referred to as "Heyao Heping"), has received the approval notice for the supplementary application for the approval of compound potassium hydrogen phosphate injection issued by the National Medical Products Administration. The approval confirms that the product has passed the evaluation of generic drug quality and efficacy consistency. Compound potassium hydrogen phosphate injection, as a phosphorus supplement, is mainly used for: (1) correcting hypophosphatemia in adult and pediatric patients when oral or enteral nutrition is not feasible, insufficient, or contraindicated; (2) used for parenteral nutrition in adult and pediatric patients when oral or enteral nutrition is not feasible, insufficient, or contraindicated. In July 2024, Heyao Heping submitted the supplementary application for the consistency evaluation of compound potassium hydrogen phosphate injection to the National Medical Products Administration Drug Evaluation Center and it has been accepted. As of now, Heyao Heping has invested approximately 9.21 million yuan in the research and development of compound potassium hydrogen phosphate injection.